OTCMKTS:ACUS Acusphere (ACUS) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock AnalysisChart About Acusphere Stock (OTCMKTS:ACUS) Get Acusphere alerts:Sign Up Key Stats Today's Range N/A50-Day Range N/A52-Week Range N/AVolumeN/AAverage VolumeN/AMarket CapitalizationN/AP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview Acusphere, Inc. was a specialty pharmaceutical company focused on developing drug-delivery technologies and pharmaceutical products for cardiovascular, respiratory, and other medical conditions. The company’s work centered on proprietary particle-based formulations intended to improve the delivery, effectiveness, or tolerability of existing therapeutic compounds. Acusphere’s historical development portfolio included AeroLEF, an inhaled formulation being evaluated for the treatment of acute pain, and AI-700, an inhaled contrast agent investigated for use in the diagnosis of pulmonary embolism. These products were development-stage candidates and were not established as broadly marketed medicines. The company was based in the United States and conducted its development activities primarily through clinical research and partnerships. Publicly available information about Acusphere’s current operations, leadership, and geographic reach is limited, and the company appears to have significantly reduced its activities after its historical product-development programs.AI Generated. May Contain Errors. Read More Receive ACUS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Acusphere and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. ACUS Stock News HeadlinesThis Vibrating Massage Ball Fits Into The Palm Of Your Hand — And Serves As An Affordable Alternative To The SpaOctober 26, 2025 | msn.comThis Palm-Sized Massage Ball Is An Affordable Alternative To The SpaOctober 24, 2025 | msn.comAI Microcap Teams With Gentex on Next-Gen Military HelmetsMorgan Stanley projects the humanoid robotics market could reach $5 trillion by 2050, with more than 1 billion robots operating worldwide. But even the most advanced machines still lack one human sense: smell. One microcap is developing an AI-powered sensor, smaller than a deck of cards, now in hands-on integration with Gentex, whose helmet systems serve U.S. forces and more than 20 NATO nations.October 14 at 1:00 AM | Capital Trends (Ad)ECLP Eclipse Bancorp, Inc.November 14, 2024 | seekingalpha.comGuizhou Aviation Technical Development Co Ltd (688239)July 25, 2023 | investing.comHealthcare StocksJune 24, 2023 | morningstar.comMAcusphere Stock (OTC:ACUS), Insider Trading ActivityMay 16, 2023 | benzinga.comNanotechnology Market Size, Trends and Forecast 2030March 27, 2023 | marketwatch.comSee More Headlines Company Calendar Today10/14/2026Fiscal Year End12/31/2026Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeOTCMKTS SectorHealthcare Industry Pharmaceuticals Sub-IndustryPharmaceuticals Current SymbolOTCMKTS:ACUS CIKN/A Webwww.acusphere.com Phone(617) 648-8800Fax978-863-9993Employees118Year FoundedN/AProfitability EPS (Trailing Twelve Months)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding SharesN/AFree FloatN/AMarket CapN/A OptionableNot Optionable BetaN/A The 10 Best High-Yield Dividend Stocks for 2026Discover the 10 Best High-Yield Dividend Stocks for 2026 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.Get This Free Report This page (OTCMKTS:ACUS) was last updated on 10/12/2026 by MarketBeat.com Staff. From Our PartnersElon Musk’s One Stock Retirement PlanJeff Brown picked Nvidia in 2016, before it surged 37,000 percent. Now he's tracking a small AI company he say...Brownstone Research | SponsoredTrump's about to unleash his Midterm WeaponTrump is turning the midterms into a referendum on American energy, pushing for more oil, more gas, and lower ...Monument Traders Alliance | SponsoredWall Street legend reveals his top AI stock before Oct. 20Marc Chaikin, the 60-year Wall Street veteran behind the Power Gauge rating system, has flagged a new AI stock...Chaikin Analytics | SponsoredThe Iran War Isn’t Chaos. It’s Strategy.Two thousand missiles struck Iran. Three days later, Dylan Jovine sat in two private meetings with U.S. Congre...Behind the Markets | SponsoredHow one AI fund pays investors every ThursdayOne small fund tied to artificial intelligence stocks delivered $1,051 in a single month, not through selling ...Investors Alley | SponsoredINSANE DRONE FOOTAGENew drone footage shows a mysterious factory rising at one of Elon Musk's most secure facilities, cleared and ...Paradigm Press | SponsoredFederal Reserve Reveals Disturbing New Plan To Control Your MoneyA Federal Reserve filing, Docket No. OP-1670, is drawing scrutiny for language that could expand the Fed's vis...Weiss Ratings | SponsoredA letter from Shannon StansberryPorter Stansberry nearly canceled the entire project. When he first saw the claimed returns - only one down ye...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Acusphere Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Acusphere With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.